 |
|
|
| |
The Single-Tablet, Fixed-Dose Regimen of Elvitegravir/GS-9350/Emtricitabine/Tenofovir DF (Quad) Achieves a High Rate of Virologic Suppression and GS-9350 is an Effective Booster
|
| |
| |
Reported by Jules Levin
CROI SF 2010 Feb 16-19
Calvin Cohen1, David Shamblaw2, Peter Ruane3, Richard Elion4, Edwin DeJesus5, HuiC. Liu6, LijieZhong6, David Warren6, Brian P. Kearney6, and Steven L. Chuck6
1Community Research Initiative of New England, Boston, MA; 2San Diego, CA;
3Los Angeles, CA; 4Whitman Walker Clinic, Washington, D.C.;
5Orlando Immunology Center, Orlando, FL; and 6Gilead Sciences, Foster City,
|
| |
|
|
|
|
|
